Therapeutic Protocols for Ambulatory Patients
Study & PI
|Hopkins Opportunities for Participant Engagement (HOPE) Registry|
PI: Daniel Ford, MD, MPH
Hopkins Opportunities for Participant Engagement (HOPE) Registry
If you are considering participation in research related to the prevention, diagnosis or treatment of COVID-19, please consider joining the HOPE Registry.
To volunteer, you must complete a short 5 minute survey. Participation in the survey is voluntary. Click here to complete the survey.
To learn more visit: http://johnshopkinshope.org/
|Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized, Double-Blind, Controlled, Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune) Plasma Among Outpatients with Symptomatic COVID-19 |
PI: David Sullivan
|Enroll: 888-506-1199 or visit www.covidplasmatrial.org
This study will assess the efficacy and safety of Human Coronavirus Immune Plasma (HCIP) to reduce the risk of hospitalization or death in adults who are positive by RNA detection for SARS-CoV-2 and have at least one symptom of COVID-19. In addition, the impact of HCIP on the duration of symptoms and nasopharyngeal or oropharyngeal viral shedding will be assessed. Eligible subjects will be stratified 50:50 in the <65 vs > 65 age range and will be randomized in a 1:1 ratio to receive either HCIP or control plasma.
|A 5401/ACTIV-2: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), version 1.0, dated 07/07/2020|
PI: Kelly Dooley
|This is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19. It begins with a phase II evaluation, followed by a transition into a larger phase III evaluation for promising agents. The trial is a multicenter, randomized, blinded, controlled adaptive platform that allows agents to be added and dropped during the course of the study for efficient testing of new agents against placebo within the same trial infrastructure. At least 50% of participants will meet the protocol definition of being at “high” risk of progression to severe COVID-19. Randomization in both phase II and phase III will be stratified by 1) time from symptom onset and 2) “high” versus “low” risk of progression to severe COVID-19.|
|COMBO Trial (Camostat with Bicalutamide) for COVID-19|
PI: Cathy Handy Marshall
|This randomized study will test whether either of 2 strategies to try and reduce the activity of the TMPRSS2 protease, which is required for SARS-CoV2 infectivity and viral spread, will be able to improve outcomes in outpatients diagnosed with COVID -19. The protease inhibitor camostat has the potential to directly inhibit TMPRSS2’s proteolytic activity, while the antiandrogen bicalutamide can downregulate its expression. Male and female patients who are ≥ 60 years of age with symptomatic COVID-19 and are within 5 days of a positive PCR test will be randomized 1:1:1 to 7 days of treatment with standard of care alone or with oral camostat or with oral camostat+bicalutamide.|